Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02306135 · ClinicalTrials.gov registry record
Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT02306135: Clinical Trial study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT02306135 is a clinical trial that was terminated before completion, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02306135 was terminated before completion, sponsored by Dartmouth-Hitchcock Medical Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation, and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric inhibitor of mTOR that suppresses mTORC1 activity. Everolimus is FDA-approved for the treatment of ER+/HER2- breast cancer (in combination with exemestane), renal cell carcinoma, subependymal giant cell astrocytoma (SEGA), and neuroendocrine tumors of pancreatic origin (PNET), and is currently being tested in ongoing clinical studies in other indications. While everolimus-based therapies elicit anti-cancer effects, most cancers ultimately progress and exhibit everolimus resistance. This study will evaluate genetic mechanisms of resistance to everolimus.
Interventions
- OTHER n/a- this is an observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-03 |
Why NCT02306135 stopped before completion
NCT02306135 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which n/a- this is an observational study is the first listed.
NCT02306135 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02306135 about?
NCT02306135 is a clinical study titled "Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer". mTOR kinase is part of the mTORC1 complex that promotes cap-dependent protein translation, and part of the mTORC2 complex that activates AKT. Everolimus (Afinitor) is an allosteric inhibitor of mTOR that suppresses mTORC1 activity. Everolimus is FDA-approved for the treatment of ER+/HER2- breast can...
What is the current status of trial NCT02306135?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2015-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02306135?
The interventions under investigation include: n/a- this is an observational study (OTHER).
Who is sponsoring clinical trial NCT02306135?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia